Cashu
ImmunityBio's Anktiva Gains EMA Recommendation for Bladder Cancer Treatment Advancement
about 1 month ago
Stocks
Health Care
ibrx
ImmunityBio
NASDAQ: IBRX
+1.58 (+39.87%)
5.525
USD
At close at Jan 16, 21:39 UTC
Overview
Loading chart...
Key Stats
Market Cap
5.22B
Dividend Yield
0.00%
P/E Ratio
-14.97
EPS
-0.59
Revenue
14.74M
Avg. Volume
70.74M
About
What does IBRX do?
ImmunityBio is a San Diego-based clinical stage immunotherapy company with 628 employees, focusing on therapies for urologic cancers and infectious diseases. Its lead product candidate, Anktiva, is an IL-15 superagonist fusion protein.
Sector
💻 Health Care
IPO
CEO
Employees
680
Headquarters
California, USA
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.